{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:17:01Z","timestamp":1794939421806,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68493-2","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:03:02Z","timestamp":1768903382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression"],"prefix":"10.1038","volume":"17","author":[{"given":"Xiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0551-2916","authenticated-orcid":false,"given":"Haoxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-3909","authenticated-orcid":false,"given":"Colin R.","family":"Goding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2590-0475","authenticated-orcid":false,"given":"Rutao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0859-3923","authenticated-orcid":false,"given":"Tongzheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"68493_CR1","first-page":"e071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple-negative breast cancer. BMJ (Clin. Res. ed.) 381, e071674 (2023).","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"68493_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 9, 176\u2013198 (2019).","journal-title":"Cancer Discov."},{"key":"68493_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14186","volume":"8","author":"J Liu","year":"2017","unstructured":"Liu, J. et al. A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via regulation of IRE1\u03b1 stability. Nat. Commun. 8, 14186 (2017).","journal-title":"Nat. Commun."},{"key":"68493_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.cell.2020.02.017","volume":"180","author":"JR Liang","year":"2020","unstructured":"Liang, J. R. et al. A genome-wide ER-phagy screen highlights key roles of mitochondrial metabolism and ER-resident UFMylation. Cell 180, 1160\u20131177.e1120 (2020).","journal-title":"Cell"},{"key":"68493_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41418-022-01041-9","volume":"30","author":"Y Tao","year":"2023","unstructured":"Tao, Y. et al. UFL1 promotes antiviral immune response by maintaining STING stability independent of UFMylation. Cell Death Differ. 30, 16\u201326 (2023).","journal-title":"Cell Death Differ."},{"key":"68493_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.molcel.2024.01.024","volume":"84","author":"C He","year":"2024","unstructured":"He, C. et al. UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. Mol. cell 84, 1120\u20131138.e1128 (2024).","journal-title":"Mol. cell"},{"key":"68493_CR7","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1093\/nar\/gkz110","volume":"47","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. MRE11 UFMylation promotes ATM activation. Nucleic Acids Res. 47, 4124\u20134135 (2019).","journal-title":"Nucleic Acids Res."},{"key":"68493_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09175-0","volume":"10","author":"B Qin","year":"2019","unstructured":"Qin, B. et al. UFL1 promotes histone H4 ufmylation and ATM activation. Nat. Commun. 10, 1242 (2019).","journal-title":"Nat. Commun."},{"key":"68493_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.molcel.2014.08.007","volume":"56","author":"HM Yoo","year":"2014","unstructured":"Yoo, H. M. et al. Modification of ASC1 by UFM1 is crucial for ER\u03b1 transactivation and breast cancer development. Mol. cell 56, 261\u2013274 (2014).","journal-title":"Mol. cell"},{"key":"68493_CR10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41556-020-0559-z","volume":"22","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination. Nat. Cell Biol. 22, 1056\u20131063 (2020).","journal-title":"Nat. Cell Biol."},{"key":"68493_CR11","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/cdd.2015.51","volume":"22","author":"M Zhang","year":"2015","unstructured":"Zhang, M. et al. RCAD\/Ufl1, a Ufm1 E3 ligase, is essential for hematopoietic stem cell function and murine hematopoiesis. Cell Death Differ. 22, 1922\u20131934 (2015).","journal-title":"Cell Death Differ."},{"key":"68493_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1182","volume":"2","author":"K Tatsumi","year":"2011","unstructured":"Tatsumi, K. et al. The Ufm1-activating enzyme Uba5 is indispensable for erythroid differentiation in mice. Nat. Commun. 2, 181 (2011).","journal-title":"Nat. Commun."},{"key":"68493_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-023-02681-6","volume":"42","author":"F Chen","year":"2023","unstructured":"Chen, F. et al. Loss of Ufl1\/Ufbp1 in hepatocytes promotes liver pathological damage and carcinogenesis through activating mTOR signaling. J. Exp. Clin. cancer Res.: CR 42, 110 (2023).","journal-title":"J. Exp. Clin. cancer Res.: CR"},{"key":"68493_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.14348\/molcells.2022.0029","volume":"45","author":"HM Yoo","year":"2022","unstructured":"Yoo, H. M., Park, J. H., Kim, J. Y. & Chung, C. H. Modification of ER\u03b1 by UFM1 increases its stability and transactivity for breast cancer development. Mol. cells 45, 425\u2013434 (2022).","journal-title":"Mol. cells"},{"key":"68493_CR15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.6004\/jnccn.2013.0086","volume":"11","author":"J Lauring","year":"2013","unstructured":"Lauring, J., Park, B. H. & Wolff, A. C. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J. Natl. Compr. Canc. Netw. 11, 670\u2013678 (2013).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"68493_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-021-01137-8","volume":"14","author":"H Hua","year":"2021","unstructured":"Hua, H. et al. Targeting Akt in cancer for precision therapy. J. Hematol. Oncol. 14, 128 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"68493_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.onc.1201947","volume":"17","author":"A Bellacosa","year":"1998","unstructured":"Bellacosa, A. et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17, 313\u2013325 (1998).","journal-title":"Oncogene"},{"key":"68493_CR18","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/ncb1795","volume":"10","author":"M Higuchi","year":"2008","unstructured":"Higuchi, M., Onishi, K., Kikuchi, C. & Gotoh, Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat. Cell Biol. 10, 1356\u20131364 (2008).","journal-title":"Nat. Cell Biol."},{"key":"68493_CR19","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Sci. (N. Y., N. Y.) 307, 1098\u20131101 (2005).","journal-title":"Sci. (N. Y., N. Y.)"},{"key":"68493_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell 169, 381\u2013405 (2017).","journal-title":"Cell"},{"key":"68493_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1097-2765(02)00776-1","volume":"11","author":"S Basu","year":"2003","unstructured":"Basu, S., Totty, N. F., Irwin, M. S., Sudol, M. & Downward, J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. cell 11, 11\u201323 (2003).","journal-title":"Mol. cell"},{"key":"68493_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.molcel.2007.02.017","volume":"25","author":"J Brognard","year":"2007","unstructured":"Brognard, J., Sierecki, E., Gao, T. & Newton, A. C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. cell 25, 917\u2013931 (2007).","journal-title":"Mol. cell"},{"key":"68493_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molcel.2005.03.008","volume":"18","author":"T Gao","year":"2005","unstructured":"Gao, T., Furnari, F. & Newton, A. C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. cell 18, 13\u201324 (2005).","journal-title":"Mol. cell"},{"key":"68493_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cell.2009.01.025","volume":"136","author":"S Padmanabhan","year":"2009","unstructured":"Padmanabhan, S. et al. A PP2A regulatory subunit regulates C. elegans insulin\/IGF-1 signaling by modulating AKT-1 phosphorylation. Cell 136, 939\u2013951 (2009).","journal-title":"Cell"},{"key":"68493_CR25","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/leu.2011.146","volume":"25","author":"PP Ruvolo","year":"2011","unstructured":"Ruvolo, P. P. et al. Low expression of PP2A regulatory subunit B55\u03b1 is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 25, 1711\u20131717 (2011).","journal-title":"Leukemia"},{"key":"68493_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. cell Biol. 13, 283\u2013296 (2012).","journal-title":"Nat. Rev. Mol. cell Biol."},{"key":"68493_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fimmu.2020.00307","volume":"11","author":"S Qin","year":"2020","unstructured":"Qin, S. et al. SHIP-1 regulates phagocytosis and M2 polarization through the PI3K\/Akt-STAT5-trib1 circuit in pseudomonas aeruginosa infection. Front. Immunol. 11, 307 (2020).","journal-title":"Front. Immunol."},{"key":"68493_CR28","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-24-1846","volume":"84","author":"E Sementino","year":"2024","unstructured":"Sementino, E., Hassan, D., Bellacosa, A. & Testa, J. R. AKT and the Hallmarks of Cancer. Cancer Res 84, 4126\u20134139 (2024).","journal-title":"Cancer Res"},{"key":"68493_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/ijms22010173","volume":"22","author":"D Miricescu","year":"2020","unstructured":"Miricescu, D. et al. PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int. J. Mol. Sci. 22, 173 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"68493_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/1078-0432.CCR-21-1943","volume":"28","author":"Y Jin","year":"2022","unstructured":"Jin, Y. et al. Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer. Clin. Cancer Res 28, 526\u2013539 (2022).","journal-title":"Clin. Cancer Res"},{"key":"68493_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target. Ther. 6, 425 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"68493_CR32","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","volume":"24","author":"MA Khan","year":"2019","unstructured":"Khan, M. A., Jain, V. K., Rizwanullah, M., Ahmad, J. & Jain, K. PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov. Today 24, 2181\u20132191 (2019).","journal-title":"Drug Discov. Today"},{"key":"68493_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1078-0432.CCR-21-2498","volume":"28","author":"Z Shi","year":"2022","unstructured":"Shi, Z. et al. Functional mapping of AKT signaling and biomarkers of response from the FAIRLANE trial of neoadjuvant ipatasertib plus paclitaxel for triple-negative breast cancer. Clin. Cancer Res 28, 993\u20131003 (2022).","journal-title":"Clin. Cancer Res"},{"key":"68493_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395\u2013399 (2012).","journal-title":"Nature"},{"key":"68493_CR35","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).","DOI":"10.1038\/nature11412"},{"key":"68493_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","volume":"30","author":"J Pascual","year":"2019","unstructured":"Pascual, J. & Turner, N. C. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann. Oncol. 30, 1051\u20131060 (2019).","journal-title":"Ann. Oncol."},{"key":"68493_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-136","volume":"10","author":"A S\u00e1nchez-Mu\u00f1oz","year":"2010","unstructured":"S\u00e1nchez-Mu\u00f1oz, A. et al. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 10, 136 (2010).","journal-title":"BMC Cancer"},{"key":"68493_CR38","doi-asserted-by":"publisher","first-page":"108680","DOI":"10.1016\/j.pharmthera.2024.108680","volume":"260","author":"X Wang","year":"2024","unstructured":"Wang, X., Lv, X., Ma, J. & Xu, G. UFMylation: an integral post-translational modification for the regulation of proteostasis and cellular functions. Pharmacol. Ther. 260, 108680 (2024).","journal-title":"Pharmacol. Ther."},{"key":"68493_CR39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","volume":"79","author":"M Song","year":"2019","unstructured":"Song, M., Bode, A. M., Dong, Z. & Lee, M. H. AKT as a therapeutic target for cancer. Cancer Res 79, 1019\u20131031 (2019).","journal-title":"Cancer Res"},{"key":"68493_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.tem.2019.09.005","volume":"31","author":"JR Knudsen","year":"2020","unstructured":"Knudsen, J. R. et al. Growth factor-dependent and -independent activation of mTORC2. Trends Endocrinol. Metab.: TEM 31, 13\u201324 (2020).","journal-title":"Trends Endocrinol. Metab.: TEM"},{"key":"68493_CR41","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1074\/jbc.M709585200","volume":"283","author":"YC Kuo","year":"2008","unstructured":"Kuo, Y. C. et al. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J. Biol. Chem. 283, 1882\u20131892 (2008).","journal-title":"J. Biol. Chem."},{"key":"68493_CR42","doi-asserted-by":"publisher","first-page":"E2955","DOI":"10.1073\/pnas.1516321113","volume":"113","author":"Y Itoh","year":"2016","unstructured":"Itoh, Y. et al. PDK1-Akt pathway regulates radial neuronal migration and microtubules in the developing mouse neocortex. Proc. Natl. Acad. Sci. USA 113, E2955\u20132964 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68493_CR43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-021-00571-x","volume":"6","author":"L Bu","year":"2021","unstructured":"Bu, L. et al. PTEN suppresses tumorigenesis by directly dephosphorylating Akt. Signal Transduct. Target. Ther. 6, 262 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"68493_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41586-024-07073-0","volume":"627","author":"PA DaRosa","year":"2024","unstructured":"DaRosa, P. A. et al. UFM1 E3 ligase promotes recycling of 60S ribosomal subunits from the ER. Nature 627, 445\u2013452 (2024).","journal-title":"Nature"},{"key":"68493_CR45","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/s41594-025-01576-8","volume":"32","author":"K Zhao","year":"2025","unstructured":"Zhao, K. et al. Akt-phosphorylated UFL1 UFMylates ArpC4 to promote metastasis. Nat. Struct. Mol. Biol. 32, 1528\u20131541 (2025).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"68493_CR46","doi-asserted-by":"publisher","first-page":"114044","DOI":"10.1016\/j.addr.2021.114044","volume":"180","author":"M Zorko","year":"2022","unstructured":"Zorko, M., Jones, S. & Langel, \u00dc Cell-penetrating peptides in protein mimicry and cancer therapeutics. Adv. drug Deliv. Rev. 180, 114044 (2022).","journal-title":"Adv. drug Deliv. Rev."},{"key":"68493_CR47","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti, G., Brambilla, L. & Rossi, D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol. Sci. 38, 406\u2013424 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"68493_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1042\/BJ20150041","volume":"468","author":"G Risso","year":"2015","unstructured":"Risso, G., Blaustein, M., Pozzi, B., Mammi, P. & Srebrow, A. Akt\/PKB: one kinase, many modifications. Biochem. J. 468, 203\u2013214 (2015).","journal-title":"Biochem. J."},{"key":"68493_CR49","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1126\/science.1175065","volume":"325","author":"WL Yang","year":"2009","unstructured":"Yang, W. L. et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Sci. (N. Y., N. Y.) 325, 1134\u20131138 (2009).","journal-title":"Sci. (N. Y., N. Y.)"},{"key":"68493_CR50","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2012.02.065","volume":"149","author":"CH Chan","year":"2012","unstructured":"Chan, C. H. et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149, 1098\u20131111 (2012).","journal-title":"Cell"},{"key":"68493_CR51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2215732120","volume":"120","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target. Proc. Natl. Acad. Sci. USA 120, e2215732120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68493_CR52","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/neuonc\/noae272","volume":"27","author":"N Sun","year":"2024","unstructured":"Sun, N. et al. A novel nuclear RNA HSD52 scaffolding NONO\/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance. Neuro-oncol. 27, 963\u2013978 (2024).","journal-title":"Neuro-oncol."},{"key":"68493_CR53","doi-asserted-by":"publisher","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","volume":"65","author":"J Huang","year":"2022","unstructured":"Huang, J. et al. Targeting the PI3K\/AKT\/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions. J. Med Chem. 65, 16033\u201316061 (2022).","journal-title":"J. Med Chem."},{"key":"68493_CR54","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nchembio.183","volume":"5","author":"T Okuzumi","year":"2009","unstructured":"Okuzumi, T. et al. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5, 484\u2013493 (2009).","journal-title":"Nat. Chem. Biol."},{"key":"68493_CR55","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.24.00248","volume":"42","author":"HJ Burstein","year":"2024","unstructured":"Burstein, H. J., DeMichele, A., Fallowfield, L., Somerfield, M. R. & Henry, N. L. Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer-capivasertib-fulvestrant: ASCO rapid recommendation update. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 42, 1450\u20131453 (2024).","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"68493_CR56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"SJ Howell","year":"2022","unstructured":"Howell, S. J. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 23, 851\u2013864 (2022).","journal-title":"Lancet Oncol."},{"key":"68493_CR57","doi-asserted-by":"publisher","first-page":"273.e275","DOI":"10.1016\/j.ajem.2024.12.006","volume":"88","author":"A Chu","year":"2025","unstructured":"Chu, A., Hakami-Majd, N. & Whall, J. O. Acute hyperglycemic hyperosmolar syndrome associated with capivasertib, a new, oral targeted therapy for advanced breast cancer. Am. J. Emerg. Med. 88, 273.e275\u2013273.e277 (2025).","journal-title":"Am. J. Emerg. Med."},{"key":"68493_CR58","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jhep.2023.12.029","volume":"80","author":"MC Xiao","year":"2024","unstructured":"Xiao, M. C. et al. TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4\u03b1 stability. J. Hepatol. 80, 778\u2013791 (2024).","journal-title":"J. Hepatol."},{"key":"68493_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01621-w","volume":"21","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer. Mol. Cancer 21, 158 (2022).","journal-title":"Mol. Cancer"},{"key":"68493_CR60","doi-asserted-by":"publisher","first-page":"11725","DOI":"10.1039\/D3CS01066J","volume":"53","author":"P Fang","year":"2024","unstructured":"Fang, P., Pang, W. K., Xuan, S., Chan, W. L. & Leung, K. C. Recent advances in peptide macrocyclization strategies. Chem. Soc. Rev. 53, 11725\u201311771 (2024).","journal-title":"Chem. Soc. Rev."},{"key":"68493_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202205873","volume":"10","author":"T Guan","year":"2023","unstructured":"Guan, T. et al. Phosphorylation of USP29 by CDK1 Governs TWIST1 Stability and Oncogenic Functions. Adv. Sci. 10, e2205873 (2023).","journal-title":"Adv. Sci."},{"key":"68493_CR62","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.15252\/embj.201695669","volume":"36","author":"K Luo","year":"2017","unstructured":"Luo, K. et al. USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. Embo J. 36, 1434\u20131446 (2017).","journal-title":"Embo J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68493-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68493-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68493-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:03:05Z","timestamp":1768903385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68493-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68493"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68493-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}